BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loos S, Oh J, Kemper MJ. Eculizumab in STEC-HUS: need for a proper randomized controlled trial. Pediatr Nephrol 2018;33:1277-81. [PMID: 29774464 DOI: 10.1007/s00467-018-3972-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Aldridge M, Burke J. Follow-up of children with infection-associated haemolytic uraemic syndrome 1979-1995: Would eculizumab have improved prognosis? J Paediatr Child Health 2020;56:577-80. [PMID: 31705764 DOI: 10.1111/jpc.14685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Hanna RM, Barsoum M, Vandross A, Kurtz I, Burwick R. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Curr Opin Nephrol Hypertens 2019;28:278-87. [PMID: 30865166 DOI: 10.1097/MNH.0000000000000499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Monet-Didailler C, Chevallier A, Godron-Dubrasquet A, Allard L, Delmas Y, Contin-Bordes C, Brissaud O, Llanas B, Harambat J. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrol Dial Transplant 2020;35:2147-53. [PMID: 31411695 DOI: 10.1093/ndt/gfz158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
4 Yesilbas O, Yozgat CY, Akinci N, Talebazadeh F, Jafarov U, Guney AZ, Temur HO, Yozgat Y. Sudden Cardiac Arrest and Malignant Ventricular Tachycardia in an 8-Year-Old Pediatric Patient Who Has Hemolytic Uremic Syndrome Associated with Shiga Toxin-Producing Escherichia coli. J Pediatr Intensive Care 2020;9:290-4. [PMID: 33133747 DOI: 10.1055/s-0040-1708553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yesilbas O, Yozgat CY, Akinci N, Sonmez S, Tekin E, Talebazadeh F, Jafarov U, Temur HO, Yozgat Y. Acute Myocarditis and Eculizumab Caused Severe Cholestasis in a 17-Month-Old Child Who Has Hemolytic Uremic Syndrome Associated with Shiga Toxin-Producing Escherichia coli. J Pediatr Intensive Care 2021;10:216-20. [PMID: 34395040 DOI: 10.1055/s-0040-1713111] [Reference Citation Analysis]
6 Jourde-Chiche N, Fakhouri F, Dou L, Bellien J, Burtey S, Frimat M, Jarrot PA, Kaplanski G, Le Quintrec M, Pernin V, Rigothier C, Sallée M, Fremeaux-Bacchi V, Guerrot D, Roumenina LT. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol 2019;15:87-108. [PMID: 30607032 DOI: 10.1038/s41581-018-0098-z] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 34.7] [Reference Citation Analysis]
7 Detzner J, Pohlentz G, Müthing J. Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome. Toxins (Basel) 2020;12:E373. [PMID: 32512916 DOI: 10.3390/toxins12060373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Çelakil ME, Yücel BB, Bek K. CFH and CFB mutations in Shiga toxin-associated haemolytic uraemic syndrome in a 6-year-old boy. Paediatr Int Child Health 2020;40:129-31. [PMID: 31242818 DOI: 10.1080/20469047.2019.1616458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 El Qaidi S, Zhu C, McDonald P, Roy A, Maity PK, Rane D, Perera C, Hardwidge PR. High-Throughput Screening for Bacterial Glycosyltransferase Inhibitors. Front Cell Infect Microbiol 2018;8:435. [PMID: 30619781 DOI: 10.3389/fcimb.2018.00435] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
10 Hanna RM, Henriksen K, Kalantar-Zadeh K, Ferrey A, Burwick R, Jhaveri KD. Thrombotic Microangiopathy Syndromes-Common Ground and Distinct Frontiers. Adv Chronic Kidney Dis 2022;29:149-160.e1. [PMID: 35817522 DOI: 10.1053/j.ackd.2021.11.006] [Reference Citation Analysis]
11 Lingwood C. Verotoxin Receptor-Based Pathology and Therapies. Front Cell Infect Microbiol 2020;10:123. [PMID: 32296648 DOI: 10.3389/fcimb.2020.00123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]